158 related articles for article (PubMed ID: 31439119)
1. Second nationwide anti-tuberculosis drug resistance survey in Namibia.
Ruswa N; Mavhunga F; Roscoe JC; Beukes A; Shipiki E; van Gorkom J; Sawadogo S; Agolory S; Menzies H; Tiruneh D; Makumbi B; Bayer B; Zezai A; Campbell P; Alexander H; Kalisvaart N; Forster N
Int J Tuberc Lung Dis; 2019 Jul; 23(7):858-864. PubMed ID: 31439119
[TBL] [Abstract][Full Text] [Related]
2. Low prevalence of MDR-TB in Lao PDR: results from the first national anti-tuberculosis drug resistance survey.
Iem V; Dean A; Zignol M; Vongvichit P; Inthavong D; Siphanthong S; Sorsavanh T; Kim SJ; Shin S; Sébert J; Chittamany P
Trop Med Int Health; 2019 Apr; 24(4):421-431. PubMed ID: 30663180
[TBL] [Abstract][Full Text] [Related]
3. Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.
Chatla C; Jaju J; Achanta S; Samyuktha R; Chakramahanti S; Purad C; Chepuri R; Nair SA; Parmar M
Indian J Tuberc; 2018 Jul; 65(3):218-224. PubMed ID: 29933863
[TBL] [Abstract][Full Text] [Related]
4. Increase in anti-tuberculosis drug resistance in Botswana: results from the fourth National Drug Resistance Survey.
Menzies HJ; Moalosi G; Anisimova V; Gammino V; Sentle C; Bachhuber MA; Bile E; Radisowa K; Kachuwaire O; Basotli J; Maribe T; Makombe R; Shepherd J; Kim B; Samandari T; El-Halabi S; Chirenda J; Cain KP
Int J Tuberc Lung Dis; 2014 Sep; 18(9):1026-33. PubMed ID: 25189548
[TBL] [Abstract][Full Text] [Related]
5. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
Steingart KR; Schiller I; Horne DJ; Pai M; Boehme CC; Dendukuri N
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD009593. PubMed ID: 24448973
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of tuberculosis, multidrug resistant tuberculosis and associated risk factors among smear negative presumptive pulmonary tuberculosis patients in Addis Ababa, Ethiopia.
Sinshaw W; Kebede A; Bitew A; Tesfaye E; Tadesse M; Mehamed Z; Yenew B; Amare M; Dagne B; Diriba G; Alemu A; Getahun M; Fikadu D; Desta K; Tola HH
BMC Infect Dis; 2019 Jul; 19(1):641. PubMed ID: 31324227
[TBL] [Abstract][Full Text] [Related]
7. Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region.
Coovadia YM; Mahomed S; Pillay M; Werner L; Mlisana K
PLoS One; 2013; 8(11):e77712. PubMed ID: 24223122
[TBL] [Abstract][Full Text] [Related]
8. Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan.
van den Hof S; Tursynbayeva A; Abildaev T; Adenov M; Pak S; Bekembayeva G; Ismailov S
Int J Tuberc Lung Dis; 2013 Apr; 17(4):526-31. PubMed ID: 23485387
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of multidrug resistance in Mycobacterium tuberculosis isolates from HIV seropositive and seronegative patients with pulmonary tuberculosis in north India.
Sethi S; Mewara A; Dhatwalia SK; Singh H; Yadav R; Singh K; Gupta D; Wanchu A; Sharma M
BMC Infect Dis; 2013 Mar; 13():137. PubMed ID: 23497169
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Xpert® MTB/RIF assay and microscopy for the diagnosis of Mycobacterium tuberculosis in Namibia.
Mavenyengwa RT; Shaduka E; Maposa I
Infect Dis Poverty; 2017 Jan; 6(1):13. PubMed ID: 28086955
[TBL] [Abstract][Full Text] [Related]
11. The fourth national anti-tuberculosis drug resistance survey in Viet Nam.
Nhung NV; Hoa NB; Sy DN; Hennig CM; Dean AS
Int J Tuberc Lung Dis; 2015 Jun; 19(6):670-5. PubMed ID: 25946357
[TBL] [Abstract][Full Text] [Related]
12. Use of Xpert(®) MTB/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan.
Tahseen S; Qadeer E; Khanzada FM; Rizvi AH; Dean A; Van Deun A; Zignol M
Int J Tuberc Lung Dis; 2016 Apr; 20(4):448-55. PubMed ID: 26970152
[TBL] [Abstract][Full Text] [Related]
13. Relatively low primary drug resistant tuberculosis in southwestern Ethiopia.
Abebe G; Abdissa K; Abdissa A; Apers L; Agonafir M; de-Jong BC; Colebunders R
BMC Res Notes; 2012 May; 5():225. PubMed ID: 22574696
[TBL] [Abstract][Full Text] [Related]
14. Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa.
Cox HS; McDermid C; Azevedo V; Muller O; Coetzee D; Simpson J; Barnard M; Coetzee G; van Cutsem G; Goemaere E
PLoS One; 2010 Nov; 5(11):e13901. PubMed ID: 21085569
[TBL] [Abstract][Full Text] [Related]
15. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
Steingart KR; Sohn H; Schiller I; Kloda LA; Boehme CC; Pai M; Dendukuri N
Cochrane Database Syst Rev; 2013 Jan; (1):CD009593. PubMed ID: 23440842
[TBL] [Abstract][Full Text] [Related]
16. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
[TBL] [Abstract][Full Text] [Related]
17. A cross-sectional study of tuberculosis drug resistance among previously treated patients in a tertiary hospital in Accra, Ghana: public health implications of standardized regimens.
Forson A; Kwara A; Kudzawu S; Omari M; Otu J; Gehre F; de Jong B; Antonio M
BMC Infect Dis; 2018 Apr; 18(1):149. PubMed ID: 29606091
[TBL] [Abstract][Full Text] [Related]
18. Use of the Xpert(®) MTB/RIF assay for diagnosing pulmonary tuberculosis comorbidity and multidrug-resistant TB in obstetrics and gynaecology inpatient wards at the University Teaching Hospital, Lusaka, Zambia.
Bates M; Ahmed Y; Chilukutu L; Tembo J; Cheelo B; Sinyangwe S; Kapata N; Maeurer M; O'Grady J; Mwaba P; Zumla A
Trop Med Int Health; 2013 Sep; 18(9):1134-1140. PubMed ID: 23834035
[TBL] [Abstract][Full Text] [Related]
19. Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.
van Kampen SC; Tursynbayeva A; Koptleuova A; Murzakhmetova Z; Bigalieva L; Aubakirova M; Pak S; van den Hof S
PLoS One; 2015; 10(7):e0132514. PubMed ID: 26181578
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
